Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Leonard

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal for Immunotherapy of Cancer|May 16, 2025
Tumor location as a risk factor for severe immune-related adverse eventsSteven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Oncogene|September 22, 2019
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitorsCaitlin M O'Connor, Daniel Leonard, Danica Wiredja, et al.
Cell|April 22, 2020
Selective PP2A Enhancement through Biased Heterotrimer StabilizationDaniel Leonard, Wei Huang, Sudeh Izadmehr, et al.
Cancer Research|May 31, 2019
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial TumorigenesisSarah E Taylor, Caitlin M O'Connor, Zhizhi Wang, et al.
Acta Chirurgica Belgica|June 5, 2026
Risk factors associated with urinary tract infection within 4 days of male rectal cancer surgery in the era of enhanced recovery after surgery (ERAS) programsJean-Luc Faucheron, Fatah Tidadini, Zaher Lakkis, et al.
Nature Communications|August 1, 2024
The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivoMichael H J Rhodin, Archie C Reyes, Anand Balakrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait StrategyCarine El Sissy, Amos Kirilovsky, Marc Van den Eynde, et al.
The Journal of Clinical Investigation|May 16, 2017
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growthJaya Sangodkar, Abbey Perl, Rita Tohme, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal for Immunotherapy of Cancer|May 16, 2025
Tumor location as a risk factor for severe immune-related adverse eventsSteven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Oncogene|September 22, 2019
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitorsCaitlin M O'Connor, Daniel Leonard, Danica Wiredja, et al.
Cell|April 22, 2020
Selective PP2A Enhancement through Biased Heterotrimer StabilizationDaniel Leonard, Wei Huang, Sudeh Izadmehr, et al.
Cancer Research|May 31, 2019
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial TumorigenesisSarah E Taylor, Caitlin M O'Connor, Zhizhi Wang, et al.
Acta Chirurgica Belgica|June 5, 2026
Risk factors associated with urinary tract infection within 4 days of male rectal cancer surgery in the era of enhanced recovery after surgery (ERAS) programsJean-Luc Faucheron, Fatah Tidadini, Zaher Lakkis, et al.
Nature Communications|August 1, 2024
The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivoMichael H J Rhodin, Archie C Reyes, Anand Balakrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait StrategyCarine El Sissy, Amos Kirilovsky, Marc Van den Eynde, et al.
The Journal of Clinical Investigation|May 16, 2017
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growthJaya Sangodkar, Abbey Perl, Rita Tohme, et al.
Pageof 6